Trial Profile
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Vemurafenib in Patients With Tumors Harboring BRAF V600 Mutations
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 26 Oct 2023
Price :
$35
*
At a glance
- Drugs Vemurafenib (Primary)
- Indications CNS cancer; Ependymoma; Ewing's sarcoma; Glioma; Langerhans cell histiocytosis; Liver cancer; Neuroblastoma; Neuroectodermal tumours; Non-Hodgkin's lymphoma; Osteosarcoma; Rhabdoid tumour; Rhabdomyosarcoma; Soft tissue sarcoma; Solid tumours; Wilms' tumour
- Focus Therapeutic Use
- Acronyms Pediatric MATCH
- 28 Sep 2023 Planned End Date changed from 14 Jul 2024 to 22 Sep 2024.
- 17 Aug 2023 Planned End Date changed from 14 Jul 2023 to 14 Jul 2024.
- 15 Jul 2022 Planned End Date changed from 30 Jun 2022 to 14 Jul 2023.